Publication | Closed Access

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

Diabetes ManagementDiabetesPharmacologyClinical TrialsType 2Phase IiiPharmacotherapyDiabetes MellitusParallel-treatment TrialMedicine